Seprafilm® adhesion barrier: (2) A review of the clinical literature on intraabdominal use

Michael Peter Diamond, Ellen L. Burns, Beverly Accomando, Sadiqa Mian, Lena Holmdahl

Research output: Contribution to journalReview article

35 Citations (Scopus)

Abstract

This study seeks to provide a review of the clinical data published as of July 2011 concerning the postsurgical adhesion barrier, Seprafilm (chemically modified hyaluronic acid and carboxymethylcelulose; Genzyme Corporation, Cambridge, MA). Included articles detail the application of Seprafilm for intraabdominal uses that have been approved (on-label) and those considered investigational (off-label) by the FDA. Medline and EMBASE Drugs and Pharmaceuticals databases were searched for all original clinical Seprafilm research published as of July 2011. All human Seprafilm intraabdominal clinical reports and studies, excluding those related to prosthetic mesh were included. Data extraction involved the systematic review of each article. The data synthesis is the summary of Seprafilm human intraabdominal clinical reports and studies describing safety and/or efficacy. The safety and efficacy of Seprafilm in reducing postoperative adhesions has been clearly demonstrated in abdominal and pelvic laparotomy. While reports have described the safe and successful use of Seprafilmfollowing laparoscopy, pediatric laparotomy, and in patients with malignancy and/or infection, the safety and efficacy of Seprafilm use in these procedures has not been definitively established in randomized controlled trials.

Original languageEnglish (US)
Pages (from-to)247-257
Number of pages11
JournalGynecological Surgery
Volume9
Issue number3
DOIs
StatePublished - Sep 1 2012
Externally publishedYes

Fingerprint

Pharmaceutical Databases
Safety
Laparotomy
Hyaluronic Acid
Seprafilm
Laparoscopy
Randomized Controlled Trials
Pediatrics
Infection
Research
Neoplasms
Clinical Studies

Keywords

  • Adhesiolysis
  • Anti-adhesion adjuvant
  • Postoperative adhesions
  • Seprafilm

ASJC Scopus subject areas

  • Surgery
  • Obstetrics and Gynecology

Cite this

Seprafilm® adhesion barrier : (2) A review of the clinical literature on intraabdominal use. / Diamond, Michael Peter; Burns, Ellen L.; Accomando, Beverly; Mian, Sadiqa; Holmdahl, Lena.

In: Gynecological Surgery, Vol. 9, No. 3, 01.09.2012, p. 247-257.

Research output: Contribution to journalReview article

Diamond, Michael Peter ; Burns, Ellen L. ; Accomando, Beverly ; Mian, Sadiqa ; Holmdahl, Lena. / Seprafilm® adhesion barrier : (2) A review of the clinical literature on intraabdominal use. In: Gynecological Surgery. 2012 ; Vol. 9, No. 3. pp. 247-257.
@article{f384a84831444552a5562f5f603d2054,
title = "Seprafilm{\circledR} adhesion barrier: (2) A review of the clinical literature on intraabdominal use",
abstract = "This study seeks to provide a review of the clinical data published as of July 2011 concerning the postsurgical adhesion barrier, Seprafilm (chemically modified hyaluronic acid and carboxymethylcelulose; Genzyme Corporation, Cambridge, MA). Included articles detail the application of Seprafilm for intraabdominal uses that have been approved (on-label) and those considered investigational (off-label) by the FDA. Medline and EMBASE Drugs and Pharmaceuticals databases were searched for all original clinical Seprafilm research published as of July 2011. All human Seprafilm intraabdominal clinical reports and studies, excluding those related to prosthetic mesh were included. Data extraction involved the systematic review of each article. The data synthesis is the summary of Seprafilm human intraabdominal clinical reports and studies describing safety and/or efficacy. The safety and efficacy of Seprafilm in reducing postoperative adhesions has been clearly demonstrated in abdominal and pelvic laparotomy. While reports have described the safe and successful use of Seprafilmfollowing laparoscopy, pediatric laparotomy, and in patients with malignancy and/or infection, the safety and efficacy of Seprafilm use in these procedures has not been definitively established in randomized controlled trials.",
keywords = "Adhesiolysis, Anti-adhesion adjuvant, Postoperative adhesions, Seprafilm",
author = "Diamond, {Michael Peter} and Burns, {Ellen L.} and Beverly Accomando and Sadiqa Mian and Lena Holmdahl",
year = "2012",
month = "9",
day = "1",
doi = "10.1007/s10397-012-0742-8",
language = "English (US)",
volume = "9",
pages = "247--257",
journal = "Gynecological Surgery",
issn = "1613-2076",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - Seprafilm® adhesion barrier

T2 - (2) A review of the clinical literature on intraabdominal use

AU - Diamond, Michael Peter

AU - Burns, Ellen L.

AU - Accomando, Beverly

AU - Mian, Sadiqa

AU - Holmdahl, Lena

PY - 2012/9/1

Y1 - 2012/9/1

N2 - This study seeks to provide a review of the clinical data published as of July 2011 concerning the postsurgical adhesion barrier, Seprafilm (chemically modified hyaluronic acid and carboxymethylcelulose; Genzyme Corporation, Cambridge, MA). Included articles detail the application of Seprafilm for intraabdominal uses that have been approved (on-label) and those considered investigational (off-label) by the FDA. Medline and EMBASE Drugs and Pharmaceuticals databases were searched for all original clinical Seprafilm research published as of July 2011. All human Seprafilm intraabdominal clinical reports and studies, excluding those related to prosthetic mesh were included. Data extraction involved the systematic review of each article. The data synthesis is the summary of Seprafilm human intraabdominal clinical reports and studies describing safety and/or efficacy. The safety and efficacy of Seprafilm in reducing postoperative adhesions has been clearly demonstrated in abdominal and pelvic laparotomy. While reports have described the safe and successful use of Seprafilmfollowing laparoscopy, pediatric laparotomy, and in patients with malignancy and/or infection, the safety and efficacy of Seprafilm use in these procedures has not been definitively established in randomized controlled trials.

AB - This study seeks to provide a review of the clinical data published as of July 2011 concerning the postsurgical adhesion barrier, Seprafilm (chemically modified hyaluronic acid and carboxymethylcelulose; Genzyme Corporation, Cambridge, MA). Included articles detail the application of Seprafilm for intraabdominal uses that have been approved (on-label) and those considered investigational (off-label) by the FDA. Medline and EMBASE Drugs and Pharmaceuticals databases were searched for all original clinical Seprafilm research published as of July 2011. All human Seprafilm intraabdominal clinical reports and studies, excluding those related to prosthetic mesh were included. Data extraction involved the systematic review of each article. The data synthesis is the summary of Seprafilm human intraabdominal clinical reports and studies describing safety and/or efficacy. The safety and efficacy of Seprafilm in reducing postoperative adhesions has been clearly demonstrated in abdominal and pelvic laparotomy. While reports have described the safe and successful use of Seprafilmfollowing laparoscopy, pediatric laparotomy, and in patients with malignancy and/or infection, the safety and efficacy of Seprafilm use in these procedures has not been definitively established in randomized controlled trials.

KW - Adhesiolysis

KW - Anti-adhesion adjuvant

KW - Postoperative adhesions

KW - Seprafilm

UR - http://www.scopus.com/inward/record.url?scp=84865965960&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865965960&partnerID=8YFLogxK

U2 - 10.1007/s10397-012-0742-8

DO - 10.1007/s10397-012-0742-8

M3 - Review article

AN - SCOPUS:84865965960

VL - 9

SP - 247

EP - 257

JO - Gynecological Surgery

JF - Gynecological Surgery

SN - 1613-2076

IS - 3

ER -